GILD Nov 2023 60.000 put
| Previous Close | 1.0000 |
| Open | 1.0000 |
| Bid | 0.8500 |
| Ask | 1.1100 |
| Strike | 60.00 |
| Expire Date | 2023-11-17 |
| Day's Range | 1.0000 - 1.0000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 3.98k |
Business WireGilead and Kite Oncology Demonstrate Growing Hematology Pipeline and Strength of Leading Cell Therapy Portfolio at EHA
FOSTER CITY, Calif. & SANTA MONICA, Calif., June 01, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present 17 abstracts from its industry-leading cell therapy portfolio and growing blood cancer pipeline at the upcoming 2023 European Hematology Association (EHA) Annual Congress being held in Frankfurt, Germany, June 8-11, and virtually June 14-15.
ACCESSWIREBilal Piperdi on How Gilead Is Striving To Create New Possibilities for People With Lung Cancer
After finishing medical school in the late 1990s, Bilal Piperdi wanted to follow his mentor into the field of thoracic oncology, the specialized area that focuses on lung cancer.
Simply Wall St.Gilead Sciences (NASDAQ:GILD) Is Paying Out A Larger Dividend Than Last Year
Gilead Sciences, Inc.'s ( NASDAQ:GILD ) dividend will be increasing from last year's payment of the same period to...
ZacksGilead's (GILD) Veklury Gets Positive CHMP View for Extended Use
Gilead (GILD) obtains positive opinion for the use of Veklury in COVID-19 patients with severe renal impairment, including those on dialysis, from the European Medicines Agency's CHMP.
Business WireCHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Severe Renal Impairment, Including Those on Dialysis
FOSTER CITY, Calif., May 26, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) granted a positive opinion for the use of Veklury® (remdesivir) in COVID-19 patients with severe renal impairment, including those on dialysis. The European Commission (EC) will review the CHMP recommendation and, if adopted, Veklury will become the first and only authorized antiviral COVID-19 treatment that
Business WireGilead Sciences to Present at Upcoming Investor Conference
FOSTER CITY, Calif., May 25, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conference:
- ACCESSWIRE
How Gilead’s Supportive Culture Helps Working Parents: LJ’s Story
NORTHAMPTON, MA / ACCESSWIRE / May 25, 2023 / Gilead Sciences When LJ Mizzi joined Gilead in 2013, she already had a personal connection to the company. "A Gilead medicine saved the life of a loved one, so I was excited to begin a career here ...
- Simply Wall St.
Here's Why Gilead Sciences (NASDAQ:GILD) Can Manage Its Debt Responsibly
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
- Simply Wall St.
Gilead Sciences, Inc. (NASDAQ:GILD) is favoured by institutional owners who hold 85% of the company
Key Insights Given the large stake in the stock by institutions, Gilead Sciences' stock price might be vulnerable to...
Motley Fool3 Relatively Safe Stocks to Buy if a Recession Is on the Way
Here's why three Motley Fool contributors think that AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Johnson & Johnson (NYSE: JNJ) are relatively safe stocks to buy if a recession is declared this year. Prosper Junior Bakiny (AbbVie): It may be hard to believe that AbbVie is a safe stock right now.
- Reuters
Former Immunomedics CFO pleads guilty to insider trading
The former chief financial officer of a New Jersey biotechnology company pleaded guilty on Wednesday to insider trading, after prosecutors said he had given nonpublic information about a new breast cancer drug to his girlfriend at the time. Usama Malik, 48, former CFO of Immunomedics Inc, now owned by Gilead Sciences Inc, admitted to a single charge of securities fraud at a hearing before U.S. District Judge John Michael Vazquez in Newark, New Jersey.
Business WireGilead and Kite Oncology to Showcase Advances Across the Pipeline Aiming to Address Unmet Needs in Cancer Care at ASCO 2023
FOSTER CITY, Calif. & SANTA MONICA, Calif., May 17, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present 30 abstracts during the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. These data reinforce the strength of Gilead and Kite Oncology’s transformative science in hard-to-treat cancers.
Business WireGilead Appoints Cindy Perettie Executive Vice President of Kite
FOSTER CITY, Calif., May 16, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Cindy Perettie will join the company as Executive Vice President of Kite, a Gilead Company, overseeing the cell therapy business, and will become a member of Gilead’s senior leadership team, effective May 30.
ZacksArcus (RCUS) & Gilead Re-Collaborate for Inflammatory Diseases
Arcus (RCUS) surges as it expands its previous research collaboration with partner Gilead, to focus on developing therapies for inflammatory diseases.
- Business Wire
Gilead Sciences and Arcus Biosciences Expand Partnership to Include Research Programs in Inflammation
FOSTER CITY, Calif., & HAYWARD, Calif., May 15, 2023--Gilead Sciences, Inc. (Nasdaq:GILD) and Arcus Biosciences, Inc. (NYSE:RCUS) today announced that the companies have expanded the previously announced research collaboration focused on oncology to include therapies for the treatment of inflammatory diseases. The expanded collaboration builds upon Gilead’s growing presence in inflammatory disease and serves as a step towards broadening Arcus’ capabilities and portfolio beyond oncology and into
Motley FoolGilead Sciences Stock: Bear vs. Bull
You may know of Gilead Sciences (NASDAQ: GILD) because of its blockbuster coronavirus treatment Veklury. In fact, the S&P 500 has outperformed Gilead over the past five years. Gilead has struggled to consistently deliver annual revenue growth ever since its hepatitis C portfolio's revenue reached a peak back in 2015.
- Simply Wall St.
Here's Why We Think Gilead Sciences (NASDAQ:GILD) Might Deserve Your Attention Today
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
- ACCESSWIRE
Gilead Emphasizes Unique Ways To Hire Top Talent
When Jamari Brooks was looking for a new job last fall, he knew he wanted his future employer to have a few key qualities.
- Reuters
UPDATE 1-Gilead Sciences prevails in US government lawsuit over HIV drug patents
A federal jury on Tuesday found that Gilead Sciences Inc did not infringe U.S. patents with its HIV-prevention regimens using the drugs Truvada and Descovy, handing the government a defeat in its billion-dollar lawsuit. The Delaware jury found the government's patents were invalid and not infringed following a five-day trial and a morning of deliberations. The federal government had argued that Gilead failed to compensate the U.S. Centers for Disease Control and Prevention (CDC) for discovering that its drug Truvada, which was first approved to treat HIV, could also help prevent infection by the virus.
- Reuters
Gilead Sciences prevails in US government lawsuit over HIV drug patents
A federal jury on Tuesday found that Gilead Sciences Inc did not infringe U.S. patents with its HIV-prevention regimen using the drugs Truvada and Descovy, handing the government a defeat in its billion-dollar lawsuit. The Delaware jury found the government's patents were invalid and not infringed. The federal government had argued that Gilead failed to compensate the U.S. Centers for Disease Control and Prevention (CDC) for discovering that its drug Truvada, which was first approved to treat HIV, could also help prevent infection by the virus.
Business WireGilead Strengthens Early Pipeline in Oncology and Inflammation Through the Acquisition of XinThera
FOSTER CITY, Calif., May 09, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the acquisition of all outstanding shares of XinThera, a privately held biotech company in San Diego. The acquisition complements Gilead’s existing clinical development priorities by adding additional pipeline assets for well-validated targets in oncology and inflammation.
- Simply Wall St.
Gilead Sciences, Inc. (NASDAQ:GILD) Delivered A Better ROE Than Its Industry
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
- Investing.com
InvestingPro exclusive: Vertex is a Biotech Beast + 4 More Poised to Soar
Here is your VIP list of Pro Picks for the week, offered exclusively to InvestingPro subscribers: a hand-picked selection of S&P 500 stocks that InvestingPro awarded a high financial health score of at least 2.75 out of 5.00.
Motley Fool2 Magnificent Dividend Stocks to Buy Before the Next Recession
Let's look at two great dividend stocks to consider buying before the economy worsens: Gilead Sciences (NASDAQ: GILD) and Amgen (NASDAQ: AMGN). Gilead Sciences is a biotech company with a particular focus on developing HIV medicines. It has helped Gilead Sciences' revenue stay afloat as the company failed to earn approval for important candidates.
Motley FoolGilead Sciences Stock Has Only Done This in 1 of the Past 7 Years
Gilead Sciences (NASDAQ: GILD) has a bright future ahead with HIV treatment Sunlenca obtaining approval from the Food and Drug Administration last year and cancer drug Trodelvy continuing to show strong growth. Why has Gilead Sciences stock struggled? The simple reason for Gilead's woes is that the business has had trouble generating growth.